Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas

Chetan Bettegowda, Stephen Yip, Bowen Jiang, Wei-Lien Wang, Michelle J Clarke, Aron Lazary, Marco Gambarotti, Ming Zhang, Daniel M Sciubba, Jean-Paul Wolinsky, C Rory Goodwin, Edward McCarthy, Niccole M Germscheid, Arjun Sahgal, Ziya L Gokaslan, Stefano Boriani, Peter Pal Varga, Charles G Fisher, Laurence D Rhines

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Spinal chordomas, a sub-type of primary spinal column malignancies (PSCM), are rare tumors with poor prognosis and limited understanding of the molecular drivers of neoplasia.

METHODS: Study design was a retrospective review of prospectively collected data with cross-sectional survival. Archived paraffin embedded pathologic specimens were collected for 133 patients from 6 centers within Europe and North America between 1987 and 2012. Tumor DNA was extracted and the hTERT promoter was sequenced. The hTERT mutational status was correlated to overall survival (OS) and time to first local recurrence.

RESULTS: Ninety-two chordomas, twenty-six chondrosarcomas, seven osteosarcomas, three Ewing's sarcomas, and five other malignant spinal tumors were analyzed. Median OS following surgery was 5.8 years (95% CI: 4.6 to 6.9) and median time to first local recurrence was 3.9 years (95% CI: 2.5 to 6.7). Eight chordomas, two chondrosarcomas, one Ewing's sarcoma, and one other malignant spinal tumor harbored either a C228T or C250T mutation in the hTERT promoter. In the overall cohort, all patients with hTERT mutation were alive at ten years postoperative with a median overall survival (OS) of 5.1 years (95% CI: 4.5 to 6.6)(p=0.03). hTERT promoter mutation was observed in 8.7% of spinal chordomas and 100% of chordoma patients harboring the mutation were alive at ten years postoperative compared to 67% patients without the mutation (p=0.05).

CONCLUSIONS: We report for the first time that hTERT promoter mutations C228T and C250T are present in approximately 8.7% of spinal chordomas. The presence of hTERT mutations conferred a survival benefit and could potentially be a valuable positive prognostic molecular marker in spinal chordomas.

Original languageEnglish
Pages (from-to)1005-1015
Number of pages11
JournalNeuro-Oncology
Volume21
Issue number8
DOIs
Publication statusE-pub ahead of print - Apr 12 2019

Keywords

  • hTERT
  • promoter mutation
  • chordoma
  • primary spinal column malignancy
  • survival

Fingerprint Dive into the research topics of 'Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas'. Together they form a unique fingerprint.

Cite this